cagrisema cagrilintide semaglutide phase 3 results 2024 2025 is one of the most #potent #weightloss medication developed till date! Cagrisema on an average causes 9% additional weight loss over # 2.4mg/week! Cagrisema is a fixed-dose combination of semaglutide 2.4mg + # Efficacy and safety of co-administered

Lilly sells the GLP-1/GIP drug tirzepatide as Mounjaro and Zepbound

The news: Eli Lilly and Novo Nordisk are closing in on deals with the Trump administration to exchange deep discounts on their weight loss drugs for coverage under Medicare, per Endpoints News

Supply is limited strictly to laboratory research, analytical assay development, or investigative procedures only

Diabetologia (1985) 28:13842

But they're essentially the same drug and have all been found effective in studies both in reducing weight and in controlling diabetes

Why this study matters: Evaluates the effects of GLP-induced weight loss on knee osteoarthritis symptoms in obese patients